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ABSTRACT
Background: Evidence suggests that an early interven-
tional strategy for patients with non-ST-elevation acute
coronary syndrome (NSTE-ACS) can improve health
outcomes but also increase costs when compared with a
conservative strategy.
Objective: The aim of this study was to assess the cost-
effectiveness of an early interventional strategy in
different risk groups from a UK health-service perspective.
Design: Decision-analytic model based on randomised
clinical trial data.
Main outcome measures: Costs in UK Sterling at 2003/
2004 prices and quality-adjusted life years (QALYs)
combined into an incremental cost-effectiveness ratio.
Methods: Data from the third Randomised Intervention
Trial of unstable Angina (RITA 3) was employed to
estimate rates of cardiovascular death and myocardial
infarction, costs and health-related quality of life. Cost-
effectiveness was estimated over patients’ lifetimes
within the decision-analytic model.
Results: The mean incremental cost per QALY gained for
an early interventional strategy was approximately
£55 000, £22 000 and £12 000 for patients at low,
intermediate and high risk, respectively. The early
interventional strategy is approximately 1%, 35% and 95%
likely to be cost-effective for patients at low, intermediate
and high risk, respectively, at a threshold of £20 000 per
QALY. The cost-effectiveness of early intervention in low-
risk patients is sensitive to assumptions about the
duration of the treatment effect.
Conclusion: An early interventional strategy in patients
presenting with NSTE-ACS is likely to be considered cost-
effective for patients at high and intermediate risk, but
this is less likely to be the case for patients at low risk.
Non-ST-elevation acute coronary syndrome
(NSTE-ACS) represents a major health burden to
health care systems and patients face a substantial
risk of mortality and cardiovascular events.
Although evidence suggests that the use of a
strategy of early angiography with a view to
revascularisation in the management of patients
with NSTE-ACS is associated with an increased
risk of myocardial infarction (MI) or death during
the index hospitalisation, the reduced risk subse-
quently implies an overall reduction in the risk of
MI or death.1 The 5-year follow-up of the third
Randomised Intervention Trial of unstable Angina
(RITA 3) confirmed these findings, showing that
an early interventional strategy reduced the risk of
the composite endpoint of death or MI (odds ratio
0.78, 95% CI 0.61 to 0.99).2 Furthermore, it has
been shown that an early interventional strategy
improves health-related quality of life at 1 year but
also leads to increased costs when compared with a
conservative strategy.3 In order to establish
whether an early interventional strategy should
be recommended for widespread implementation,
its cost-effectiveness needs to be assessed to
determine whether the gain in health outcomes
justifies any increased costs.
Based on data from RITA 3, rates of cardiovas-
cular death or MI, costs and health-related quality
of life were estimated and extrapolated to the
relevant lifetime time horizon within a decision-
analytic model. Since baseline risk is a potentially
important predictor of both cardiovascular events
and the effectiveness of early intervention, the
model investigated cost-effectiveness in patients
with different risk profiles at randomisation.2
Secondary analyses considered whether cost-effec-
tiveness results changed when clinical results from
a meta-analysis of trials were used in the model
and when treatment effect was allowed to vary
with baseline risk.
METHODS
Overview
The decision problem under investigation concerns
whether an early interventional (routine angiogra-
phy followed by revascularisation if clinically
indicated) or a conservative strategy (ischaemia or
symptom-driven angiography) should be recom-
mended for patients presenting with NSTE-ACS.
The analysis was undertaken from a UK health-
service perspective and costs expressed in UK
Sterling (GBP) at 2003/2004 prices. Health out-
comes were estimated in terms of quality-adjusted
life years (QALYs). Costs and QALYs were
discounted by 3.5% per annum.4
Lifetime mean costs and QALYs per patient for
each strategy were estimated using a decision-
analytic model. The model comprised two stages:
(i) a short-term decision tree representing the index
hospitalisation period and (ii) a long-term Markov
structure characterising the post-index period as
shown in fig 1. Costs and QALYs were assigned to
the outcomes of the index hospitalisation (no
event, myocardial infarction or death) and for each
year that the patient spends in each state in the
long-term Markov structure. Comprehensive
details of the statistical analyses and modelling
methods are available in a technical report. (See
supplementary report.)
Acute coronary syndromes
Heart 2008;94:717–723. doi:10.1136/hrt.2007.127340 717
 group.bmj.com on July 13, 2010 - Published by heart.bmj.comDownloaded from 
Data sources
Rates of cardiovascular death or MI, costs and health-related
quality of life were estimated from individual-patient data from
RITA 3 with additional information on non-cardiovascular
mortality rates and the effectiveness of early intervention being
incorporated from standard life-tables and meta-analyses of
published trials, respectively.
The RITA 3 trial has been described elsewhere.2 5 Briefly,
RITA 3 was a prospective, randomised multicentre trial with
parallel groups, enrolling 1810 patients from 45 hospitals in
England and Scotland, UK. Eligible patients had an episode of
cardiac pain associated with electrocardiographic or previous
arteriographic evidence of coronary artery disease, or an elevated
serum cardiac marker, and were randomised to either an early
interventional strategy or a conservative strategy. Patients in
both treatment arms received optimal medical management. In
the early interventional strategy, the aim was to also undertake
coronary arteriography within 72 h, with subsequent manage-
ment guided by the angiographic findings.2 5
Clinical effectiveness
All statistical analyses included previously identified baseline
risk factors for cardiac events and randomised treatment as
separate covariates.2 The general approach was to drop non-
significant covariates at the 5% level using a stepwise backward
selection procedure. Covariates of structural importance, such
as the treatment covariate in the estimation of event rates, were
retained regardless of statistical significance.
The risk of the combined endpoint of cardiovascular death or
MI during the index hospitalisation (defined as the time from
randomisation to hospital discharge) was estimated using
logistic regression. In fig 1, this regression is represented as
equation 1 and shows how the estimated risk is incorporated
within the cost-effectiveness model. To estimate the risk of a
composite endpoint during the remainder of the trial period
(hospital discharge to end of follow-up), a time-to-event
Weibull proportional hazards model was employed (equation
2).6 The estimated hazard was extrapolated beyond the period
of trial follow-up, updating the age coefficient to account for
the fact that this risk increases as patients age. A conservative
assumption of no continued treatment effect from the early
interventional strategy beyond 5 years was made. Alternative
assumptions concerning the duration of the treatment effect
after the 5 years of trial follow-up were investigated in separate
scenarios.
There were insufficient patients in RITA 3 to estimate
prognosis following a non-fatal MI (equation 3). Instead, the
estimated risks of a first composite endpoint were used,
adjusted with the proportionate risk for patients who had a
non-fatal MI prior to their entry into the RITA 3. A
conservative assumption was made that the early interventional
strategy would not alter this particular risk.
A separate logistic regression was used to estimate the
proportion of composite endpoints being fatal or not (equation
4). Since this equation was applied to the risk of composite
events at different stages of the model (the index and post-index
periods), a dummy variable was used to investigate whether this
proportion was different between these periods. The mortality
risk from non-cardiovascular causes was estimated using UK sex
and age-specific life-tables adjusted to exclude cardiovascular
mortality.7 8
Costs
Comprehensive resource use data were collected for patients in
RITA 3 up to 1-year follow-up and have been reported in detail
elsewhere.9 Mean costs were estimated, differentiating between
management strategies, for patients with and without a
composite endpoint of cardiovascular death or MI, using
standard OLS regression. Beyond 1 year, the analysis assumed
no difference in costs between the treatment strategies in those
patients not experiencing the composite event.
Health-related quality of life
Health-related quality-of-life (HRQoL) data were collected in
patients in RITA 3 at randomisation, 4 months, 1 year, and
yearly thereafter using the EQ-5D instrument. Methods and
results have been reported elsewhere.3 To estimate QALYs for
each treatment strategy, the patients’ time in each health state
was multiplied by quality-adjustment weights (utilities), on a
scale where 0 represents death and 1 represents full health,
which are generated from the EQ-5D instrument based on the
preferences of the UK general population.10 11 Mean HRQoL of
patients with different risk profiles at randomisation, and
changes in HRQoL after randomisation, differentiating between
the two management strategies and whether an infarction had
occurred, were estimated using regression techniques. No
difference in HRQoL between the treatment strategies was
assumed after the first year in patients not experiencing a
cardiac event. The long-term loss of HRQoL in patients who
survived an MI was assumed equivalent to the average
difference in HRQoL of patients with and without past history
of MI observed in the trial.
Analysis
The expected costs and QALYs of both strategies were
combined into an incremental cost-effectiveness ratio (ICER),
Figure 1 Model structure. CV,
cardiovascular; CVD, cardiovascular
death; MI, myocardial infarction.
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which should be interpreted as the additional cost of generating
an additional QALY.12 Many health-care systems will compare
the ICER with a threshold value to establish whether the
strategy should, in principle, be recommended for implementa-
tion.13 The National Institute for Health and Clinical Excellence
in the UK uses a threshold of around £20 000–£30 000 per
QALY gained.4
Uncertainty in cost-effectiveness was evaluated using prob-
abilistic sensitivity analysis where inputs into the analysis are
defined as probability distributions which reflect the precision
with which they are estimated.14 To investigate potential
differences in costs and QALYs in patients with different risk
profiles, the cost-effectiveness of an early interventional
strategy was estimated using the individual covariate patterns
of each patient in RITA 3. These are presented as a distribution
of mean cost-effectiveness across the sample of trial patients.
More detailed estimates are then presented for a series of
illustrative patients within the overall sample. In RITA 3, a
multivariate predictive model for death or MI within 5 years
was used to calculate a risk score defining quartiles of risk (risk
groups 1 to 4).2 Because of the much higher event rate in the top
quartile, this quartile was then further subdivided into equal-
sized top two-eighths of risk (risk groups 4a and 4b).2 The
patient characteristics of the patients with the median risk score
in each of these five risk groups were used for the more detailed
presentation of cost-effectiveness.
Alternative scenarios
Two alternative scenarios were investigated relating to the
estimation of differential effectiveness. First, a pooled treatment
effect was estimated from all randomised trials comparing early
interventional and conservative strategies in NSTE-ACS.2 15–21
Data for this analysis were extracted from an earlier published
meta-analysis1 updated with the results from the more recent
ICTUS trial,17 the long-term results of FRISC II18 and the RITA
3 analysis itself. In the second alternative scenario, an
interaction between treatment effect and risk at randomisation
was employed using the risk score defined in RITA 3.2 Details of
these analyses are available in the technical report (see
supplementary report).
Statistical analyses
All statistical analyses were performed using Stata version 7
(Stata Statistical Software: Release 7.0. College Station, TX:
Stata Corporation). The decision-analytic model was pro-
grammed and analysed in MicrosoftH Excel (Microsoft
Corporation, Redmond, Washington, USA).
RESULTS
Clinical effectiveness
The results of the analyses of effectiveness are summarised in
table 1.
Although not significant, the early interventional strategy
was associated with an increased risk of a composite endpoint
(odds ratio 1.520) during the index hospitalisation. Age and
severe angina were statistically significant risk factors associated
with an increased risk of a composite endpoint.
After the index hospitalisation, the early interventional
strategy was associated with a statistically significant lower
rate of cardiovascular death or myocardial infarction (hazard
ratio 0.621). All risk factors bar one (angina) were statistically
significant; however, the hazard ratio for angina was close to
significance and was retained in the model as a likelihood ratio
test favoured the full model. The Weibull time-to-event model
also showed that the rate of the composite endpoint declines as
time elapses from hospital discharge.
The risk of a second composite endpoint of cardiovascular
death or myocardial infarction was estimated to be about 50%
higher than the risk of a first composite endpoint. The
probability of a composite endpoint being non-fatal was higher
in the index hospitalisation than during the follow-up period.
For patients having suffered a myocardial infarction previous to
the trial, a subsequent event was more likely to be fatal.
Table 1 Estimated short-term and long-term risks of the composite endpoint of cardiovascular death or myocardial infarction and the predicted
proportion of composite events being non-fatal
Explanatory variables
Odds ratio of composite endpoint of
myocardial infarction or cardiovascular
death during the index hospitalisation
(equation 1)
(n = 1808)
Hazard ratio of composite endpoint of
myocardial infarction or cardiovascular
death from hospital discharge until end of
trial (equations 2 and 3)*
(n = 1756)
Odds ratio of composite endpoint being
non-fatal (equation 4)
(n = 261)
Odds ratio
95% lower
limit
95% upper
limit Hazard ratio
95% lower
limit
95% upper
limit Odds ratio
95% lower
limit
95% upper
limit
Age (for every 10 years over 60) 1.731 1.262 2.374 1.777 1.499 2.108 0.699 0.520 0.941
Diabetes 1.905 1.359 2.672
Previous myocardial infarction 1.471 1.087 1.990 0.492 0.286 0.847
Smoker 1.651 1.207 2.258
Pulse (for every 5 beats per minute) 1.062 1.012 1.114
ST depression 1.423 1.067 1.913
Angina (grade 3 or 4) 1.893 1.086 3.299 1.323 0.988 1.771
Male 1.372 1.007 1.869
Left bundle branch block 1.977 1.169 3.344
Randomised to early interventional
strategy
1.520 0.864 2.675 0.621 0.464 0.830
Ancillary parameter{ 0.579 0.505 0.664
Composite endpoint during the index
hospitalisation
3.040 1.614 5.726
Coefficients show proportionate increase in risk over baseline event rates where the latter relate to rates in patients in the conservative arm without any of the risk factors included
in the analyses.
*The variable indicating a previous myocardial infarction was updated to estimate Equation 3.
{Shape parameter in the Weibull model where a value less than (above) one indicates a decreasing (increasing) hazard over time.
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Costs
The results of the cost analyses are shown in table 2. During the
index hospitalisation, the early interventional strategy was
associated with a higher mean cost of £5654 compared with a
conservative strategy. This was mainly the result of the higher
number of angiographies and revascularisations in the early
interventional arm. During the first year after the index
hospitalisation, the early interventional strategy was associated
with a lower mean cost of £1106 compared with the
conservative strategy, reflecting the fact that more patients in
the conservative strategy had further symptoms that necessi-
tated revascularisation during this period. Patients had a
substantially higher mean cost, irrespective of treatment
allocation, if they suffered a myocardial infarction within the
previous year or prior to the trial.
Health-related quality of life
The results of the analyses of HRQoL are presented in table 3.
At randomisation, mean HRQoL (in terms of utilities) was
Table 2 Estimated costs during the index hospitalisation and the first
year after the index hospitalisation
Explanatory variables
Costs during the
index
hospitalisation
(n = 1808)
Costs first year after
the index
hospitalisation
(n = 1789)
Cost SE Cost SE
Constant* 1778 295 2735 248
Age (for every 10 years over 60) 878 153
Previous myocardial infarction 724 262
ST depression 1224 268
Angina (grade 3 or 4) 1034 247
Male 1035 264 586 242
Randomised to early interventional
strategy
5654 256 21106 233
Non-fatal myocardial infarction
during the index hospitalisation
6221 972
Dying during the index
hospitalisation
7947 1229
Myocardial infarction during year 5467 804
*Cost of patients in the conservative arm without any of the risk factors included in
the analyses and not suffering cardiovascular death or myocardial infarction. Other
coefficients show the additional costs for each covariate.
SE, standard error.
Table 3 Estimated HRQoL (in terms of utilities) at randomisation and
changes in HRQoL from randomisation measured by the EQ-5D index
Explanatory variables
Utility at
randomisation
(n = 1799)
Change in utility at
follow-up
(n = 1734)
Utility SE
Change in
utility SE
Constant* 0.692 0.015
Diabetes 20.051 0.021
Previous myocardial infarction 20.044 0.016 20.010 0.016
ST depression 20.066 0.015
Angina (grade 3 or 4) 20.074 0.015
Male 0.073 0.015
Randomised to conservative strategy
(4-month follow-up)
0.044 0.013
Randomised to early interventional
strategy (4-month follow-up){
0.038 0.017
Randomised to conservative strategy
(12-month follow-up)
0.038 0.008
Randomised to early interventional
strategy (12-month follow-up){
0.018 0.015
Myocardial infarction during year 20.035 0.022
*The constant shows the utility at randomisation for a patient without any of the risk
factors included in the analyses. A negative (positive) sign indicates that the risk
factor is associated with a lower (higher) utility at randomisation.
{Note that coefficients represent the gain in utility in the early interventional strategy
over and above that of the conservative strategy.
SE, standard error.
Figure 2 Cost-effectiveness based on estimated mean costs and
QALYs, with and without early intervention, for patients in RITA 3
(n = 1807). ICER, incremental cost-effectiveness ratio. Risk groups
based on predicted risk of death or MI as defined in RITA 3.2
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higher for males whereas diabetes, previous myocardial infarc-
tion, ST depression and angina were associated with lower
HRQoL. In both treatment strategies HRQoL was improved at
4 months, although a greater improvement was seen with the
early interventional strategy than with the conservative
strategy. Between 4 and 12 months, HRQoL was improved
further in both treatment strategies, although the additional
gain of the early interventional strategy did not reach
conventional levels of statistical significance. An MI during
the study period was associated with lower HRQoL regardless
of treatment allocation and a previous MI prior to study
inclusion was associated with a small mean decrement in
HRQoL.
Cost-effectiveness
Base-case analysis
The predicted mean cost-effectiveness for patients with the
characteristics of each individual patient in RITA 3 is shown in
fig 2, highlighting the substantial heterogeneity in mean cost-
effectiveness between patients with different risk profiles. Using
a threshold of £20 000 per QALY, an early interventional
strategy is cost-effective for more patients in the higher-risk
groups, although there is still substantial variation in cost-
effectiveness within these risk groups.
The cost-effectiveness results of five illustrative patients
representing each risk group are shown in table 4. The early
interventional strategy has a favourable ICER and a high
probability of being cost-effective for the patients in the fourth
quartile of risk (both lower and upper risk halves of the
quartile), and a high ICER with a low probability of being cost-
effective for the patient representing the first quartile of risk.
For the patients representing the second and third quartiles of
risk, the ICERs are below conventional threshold values for the
UK.
Alternative scenarios
The estimated effectiveness and cost-effectiveness for the
alternative scenarios are shown in table 5 for the same
illustrative patients in each risk group. The pooled treatment
effects from the meta-analysis of eight trials were similar to the
treatment effect observed in RITA 3 (in both the index and
follow-up periods). Hence the estimated cost-effectiveness using
this alternative scenario is similar to that observed using data
only from RITA 3.
The analysis in which the effectiveness of early intervention
is permitted to vary according to patients’ risk showed that a
higher baseline risk was associated with an improved relative
treatment effect, although this interaction was not statistically
significant. Incorporating this interaction within the model
improved the cost-effectiveness of an early interventional
strategy in patients at high risk compared with the base-case
scenario of a common treatment effect. Conversely, for patients
at low risk, cost-effectiveness was much less favourable
compared with the base-case scenario (table 5).
Details of the sensitivity scenarios are available in the
technical report. The base-case results appeared robust to the
assumptions required for the long-term extrapolation with the
exception of the duration of the treatment effect of an early
interventional strategy after the 5 years of trial follow-up.
Extending the duration of the treatment effect beyond the
5 years observed in RITA 3 had an expected positive effect on
cost-effectiveness and hence an early interventional strategy
could be considered cost-effective in more patients under such
scenarios.
DISCUSSION
The analysis shows that, in patients presenting with NSTE-ACS
at high risk of further cardiac events, an early interventional
strategy is associated with a gain in QALYs at an additional cost
likely to be considered acceptable when compared with a
conservative strategy. However, for patients at low risk, an
early interventional strategy is associated with a high cost per
QALY gained. For patients at intermediate risk, the cost per
QALY gained is within generally accepted thresholds, so
decisions about cost-effectiveness are likely to be finely
balanced.
An important feature of the methods used in the analysis is
that, as part of the scenario analysis, all available trial evidence
was synthesised. This allowed evidence from seven trials
(additional to RITA 3) to be reflected in the cost-effectiveness
estimates. This re-estimation of the treatment effects had little
effect on mean estimates of cost-effectiveness, but this analysis
could be argued to more accurately reflect the uncertainty in the
treatment effect parameters as all randomised evidence is taken
into account.
Table 4 Cost-effectiveness results by patient risk profile
Risk group 1 Risk group 2 Risk group 3 Risk group 4a Risk group 4b
Age 45 52 52 61 66
Diabetes No No No No Yes
Previous myocardial infarction No No Yes Yes Yes
Smoker No Yes No Yes No
Pulse (beats per minute) 72 82 82 87 97
ST depression No No Yes Yes Yes
Angina (grade 3 or 4) Yes No Yes No No
Sex Female Male Male Male Male
Left bundle branch block No No No No No
Incremental cost (£) 4885 4898 6045 6538 6530
Incremental QALY 0.091 0.213 0.283 0.547 0.512
ICER (£) 53 760 22 949 21 325 11 957 12 750
Probability early interventional strategy is cost-effective at
£20 000 (£30 000) per QALY*
0.009 (0.123) 0.328 (0.749) 0.405 (0.805) 0.945 (0.984) 0.924 (0.984)
Illustrative patients based on predicted risk of death or MI as defined in RITA 3 represent each risk group.2
*Proportion of simulations in the probabilistic analysis with an ICER below £20 000 (£30 000).
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.
Acute coronary syndromes
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A key assumption in the base-case analysis is that the relative
reduction in the risk of events conferred by an early interven-
tional strategy is common across patients with different risk
profiles. This is an assumption made in a number of cost-
effectiveness studies in the cardiac field.22 23 Despite this
assumption, the cost-effectiveness of early intervention varies
according to patients’ risk profile, as the latter determines their
absolute benefit from early intervention which drives cost-
effectiveness. The appropriateness of the assumption of a
common treatment effect across risk profiles has been ques-
tioned in the clinical analysis of RITA 3.2 This showed a clear
beneficial treatment effect on the composite endpoint of death
or MI of an early interventional strategy for patients in the
upper risk half in the fourth quartile of risk, whereas in the first
and second quartiles of risk the odds ratios were close to 1. As
part of the scenario analysis, an interaction between patients’
baseline risks and the effectiveness of early intervention was
incorporated into the cost-effectiveness model. This analysis
reinforced the findings that an early interventional strategy is
likely to be considered cost-effective in patients at high risk but
not in patients at low risk. The conclusions were less clear for
patients at intermediate risk, as early intervention was less cost-
effective under this scenario compared with the assumption of a
common treatment effect.
It should be noted that the five illustrative patients for whom
cost-effectiveness is reported in tables 4 and 5 merely represent
an estimate of the mean cost-effectiveness of these risk groups.
Within each risk group substantial variation can be observed,
and therefore the results presented here by risk group should be
seen as indicative. In deciding in which patients early interven-
tion should be used, healthcare decision-makers will need to
consider specific combinations of characteristics that affect
patients’ risks, or see baseline risk as a continuous measure
rather than as categorical.
A number of previous studies have reported on the cost-
effectiveness of an early interventional strategy. The TACTICS-
TIMI 18 trial showed that the early interventional strategy was
dominated by a conservative strategy in a 6-month within-trial
analysis.24 In the long-term extrapolation, the cost per life-year
gained varied between $9500 (approximately £5200, 2000 price
level) and $17 200 (£9500) using different assumptions of long-
term treatment effect and different sources of long-term life
expectancy. The FRISC II trial reported high incremental costs
per prevented death or MI (649 000 Swedish kronor (SEK) or
approximately £48 000, 2000 price level) in a within-trial
analysis of 1 year’s duration.25 In a second economic evaluation
from the FRISC II trial, data on costs and quality of life at
2 years’ follow-up was available and extrapolated to a lifetime
perspective.26 The reported cost per QALY was 55 000 SEK
(£4100, 2002 price level). Exploring cost-effectiveness in
different subgroups did not alter the conclusions that an early
interventional strategy is cost-effective.
In general, the results from these previous studies follow a
similar trend to the findings in the present analysis, namely that
an early interventional strategy does not appear cost-effective in
the limited short-term perspective, whereas in the more relevant
long-term perspective an early interventional strategy can yield
positive health outcomes at an acceptable cost, at least in
patients at high risk. In contrast to previous studies, the present
analysis appears to demonstrate that risk stratification is likely
to have a significant impact on the cost-effectiveness of an early
interventional strategy.
Sensitivity scenarios indicated that the base-case results
appeared robust to the assumptions employed for theTa
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long-term extrapolation, with the exception of the duration of
the treatment effect after the 5-year follow-up from RITA 3.
Extending the duration of the long-term treatment effect of an
early interventional strategy beyond 5 years improved cost-
effectiveness. The extent to which this may change the decision
regarding the adoption of an early interventional strategy will
depend upon the strength of the decision-makers’ beliefs about
the duration of the treatment effect, and whether the treatment
effect is considered to be constant or is likely to vary across
different risk groups.
A limitation of the present study is that comprehensive data
on costs was only collected up to 1 year after randomisation in
RITA 3. However, the assumptions for the long-term extra-
polation were conservative for the early interventional strategy.
A further limitation is that individual-patient data was only
available from RITA 3 for the present analysis. Future work
should explore the impact of the results of employing
individual-patient data from other relevant trials.
In conclusion, the results of the present analysis show that an
early interventional strategy in patients presenting with NSTE-
ACS appears cost-effective for patients at high and intermediate
risk, but is unlikely to be so for patients at low risk.
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